![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AbbVie’s Migraine-Prevention Drug Wins FDA Approval
AbbVie’s Migraine-Prevention Drug Wins FDA Approval
AbbVie’s drug Qulipta (atogepant) has gained FDA approval for preventive treatment of episodic migraine in adults.
The drug is a calcitonin gene-related peptide (CGRP) receptor antagonist — a new focus in migraine drugs.
The first oral CGRP receptor antagonist specifically developed for the indication, Qulipta caused a 50 to 100 percent reduction in monthly migraine days among adult participants with episodic migraines in a phase 3 study.
“This approval reflects a broader shift in the treatment and management paradigm for the migraine community,” said Peter Goadsby, neurologist and principal investigator in the phase 3 study.
Upcoming Events
-
21Oct